SCHEMBL4164688

SCHEMBL4164688

O=c1[nH]cc(I)c(=O)n1Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.51
▸ HPGD P15428 3/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ P2RX4 Q99571 1/20 0.45
▸ GSK3A P49840 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ PNP P00491 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ CYP19A1 P11511 1/20 0.42
▸ PKM P14618 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MIF P14174 1/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ MAPK9 P45984 1/20 0.41
▸ PGR P06401 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4156287 0.84 KMT2A (0.48) ALDH1A1KDM4ESMN1; SMN2LMNAMEN1
SCHEMBL8231174 0.82 MIF (0.41) ALDH1A1HPGDKDM4ESMN1; SMN2MIF
SCHEMBL4158434 0.80 DAO (0.43) CYP19A1KMT2ASRC
SCHEMBL27335737 0.80 KDM4E (0.51) ALDH1A1KDM4ESMN1; SMN2P2RX4GSK3A
SCHEMBL1584775 0.80 ALDH1A1 (0.51) ALDH1A1HPGDKDM4ESMN1; SMN2P2RX4
SCHEMBL4098207 0.80 MEN1 (0.53) ALDH1A1HPGDKDM4ESMN1; SMN2CYP3A4
SCHEMBL4171496 0.79 P2RX4 (0.50) ALDH1A1KDM4ESMN1; SMN2P2RX4LMNA
SCHEMBL4165788 0.79 FEN1 (0.45) CYP19A1L3MBTL1
SCHEMBL15978138 0.79 FPR1 (0.51) ALDH1A1HPGDKDM4ESMN1; SMN2P2RX4
SCHEMBL11315740 0.79 HPGD (0.50) ALDH1A1HPGDKDM4ESMN1; SMN2P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 — — US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 — — US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 — — US disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS TK1, LCK, FYN ALDH1A1 1813/4885HPGD 1010/4885KDM4E 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback